https://www.selleckchem.com/pr....oducts/capsazepine.h
002). Median pre- and post-treatment CA-125 levels for LGSC patients were 295.5U/mL and 144U/mL (52% decrease) (p0.001). The median pre- and post-treatment CA-125 levels for HGSC patients were 767.5 and 35.6 (96% decrease) (p0.001). For LGSC patients, 4/36 (11%) had partial response (PR), 30/36 (83%) had stable disease (SD), and 2/36 (6%) had progressive disease (PD). In HGSC patients, 27/36 (75%) had PR, and 9/36 (25%) SD. Median PFS for LGSC patients was 18.5months and median OS was 47.4months. This study provides further
Like
Comment
Share
